German pharmaceutical company Merck KGaA (MRK.XE) said Tuesday it has appointed Stefan Oschmann as its new Chief Executive as of April 2016.
Mr. Oschmann will succeed Karl-Ludwig Kley, who has been CEO since April 2007 and is now retiring.
Born July 25, 1957 in Wuerzburg, Germany, Mr. Oschmann has served as member of the Merck executive board since 2011. He was initially in charge of its pharmaceutical business before being appointed deputy chairman of the executive board and deputy CEO at the start of 2015.
Before joining Merck, Mr. Oschmann worked at Merck & Co. of the U.S., which holds rights to the Merck designation but isn’t affiliated with the German Merck.
“We’re … happy to have found a successor in Stefan Oschmann early on, whose strategic foresight and strong leadership have turned Merck into a respected player in the pharma industry again,” said Johannes Baillou, chairman of the board of partners at E. Merck KG.
By Natascha Divac
Source: Wall Street Journal via MarketWatch
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
